OSR Holdings, Inc. 8-K/A

What Happened
OSR Holdings, Inc. (OSRH) filed an 8-K (May 6, 2026) to furnish exhibits relating to a definitive Global Exclusive License Agreement for VXM01 with BCM Europe dated April 29, 2026. The filing incorporates the license agreement and a related Pledge Agreement (both dated April 29, 2026), a press release dated April 29, 2026 titled “OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe,” and a Fairness Opinion from Avance Life Sciences AG dated April 21, 2026.

Key Details

• Agreement reported as a definitive Global Exclusive License Agreement for VXM01 with BCM Europe, described as an $815 million arrangement (dated April 29, 2026).
• A Pledge Agreement related to the transaction was executed on April 29, 2026.
• Company furnished a press release (April 29, 2026) announcing the $815M license deal and a Fairness Opinion from Avance Life Sciences AG (April 21, 2026).
• The exhibits were filed/incorporated by reference in the Company’s prior Form 8-K (filed April 30, 2026) and are now furnished in this 8-K (May 6, 2026).

Why It Matters
This filing documents a material licensing transaction for OSR: a global license for its candidate VXM01 with a counterparty described in the filing as BCM Europe and an aggregate value cited at $815 million. For investors, the deal could be a significant strategic and financial development depending on the license terms (upfront payments, milestones, royalties, timing). The inclusion of a third‑party fairness opinion indicates an independent assessment was obtained. Investors should review the full license and pledge agreements and the press release for the specific payment structure, milestone triggers, and timing to assess potential impact on revenue, cash flow and valuation.